Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax Trivalent Influenza Vaccine Lot Consistency Study
NCT06485752Phase 3Withdrawn
- Sponsor
- Novavax
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Nanoparticles, Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant in influenza, sponsored by Novavax. Planned start Nov 2024; status: withdrawn.
02
Drugs
trivalent hemagglutinin nanoparticle influenza vaccine + Matrix-M adjuvant
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06485752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485752.